Branded Generics Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast by 2031

The branded generics market size is projected to reach US$ 570.40 billion by 2031 from US$ 258.85 billion in 2023. The market is expected to register a CAGR of 10.38% during 2023–2031. The rising utilization of branded generics by healthcare providers and professionals is likely to remain a key trend in the market.

Branded Generics Market Analysis

Branded generics are sold under a brand name without a patent. They can be developed by a generic drug firm or the original manufacturer and marketed after the original drug's patent expires. An Abbreviated New Drug Application (ANDA) is submitted for regulatory approval, and it must be therapeutically equivalent to the original drug. Their launch benefits brand name companies as they can be produced with existing expertise, do not require separate FDA approval and can be launched before the patent expires without legal obstacles. Rising penetration of branded generics in the market and spurring government initiatives for the development of branded generics are expected to favor the growth of the market.

Branded Generics Market Overview

Major companies have been implementing various organic as well as inorganic strategies which have promoted its growth in the market. For instance, in April 2021, WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) had been published in a special issue of the Toxins Journal. The safety study of cardiovascular applications, "Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults," was included in the special edition of the Toxins Journal. The Asia Pacific market is driven by rising investments from international players in China and India, improving government support for the development of branded generics in countries such as China, growing usage of branded generics, and advancing healthcare infrastructure in the region. Therefore, the region holds vast potential for the branded generics market players to grow during the forecast period.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Branded Generics Market: Strategic Insights

Market Size Value in	US$ 235.86 Billion in 2022
Market Size Value by	US$ 414.99 Billion by 2028
Growth rate	CAGR of 9.9% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Branded Generics Market Drivers and Opportunities

Rising Penetration of Branded Generics to Favor Market

As per the report released by VOXEU, branded generics are cheaper alternatives to other drugs. The utilization of branded generics has increased among the population due to cost savings provided by the healthcare system and the ability to make investments in tomorrow's new medicines. According to a report published by the International Generic and Biosimilar Medicine Association (IGBA) in May 2021, generics account for 60-80% of all medicine volume sales in major global markets, with even higher levels in some countries (e.g., more than 90% in the US, over 80% in Australia, more than 90% in India, and ~ 85% in Jordan). The industry's ability to maintain cost-effective prices, combined with scale, has allowed the industry to expand the reach and access of various therapies worldwide significantly. For example, within a year of the launch of generic antivirals for hepatitis C, the number of people who started treatment increased by 50%. Therefore, expanding the penetration of generics is the major driver of global branded generics' market share.

Proclivity Towards Personalized Medicine Brings Future Opportunities

Precision medicine is advancing healthcare by tailoring treatment to each person's unique genetic makeup. This approach, also known as individualized medicine or genomic medicine, uses genetics and genomics to provide better disease prevention, more accurate diagnoses, safer drug prescriptions, and more effective treatments for various health conditions. Branded generics offer the same pharmacological effects and are cost-effective. These advantages of branded generics make them a better option for personalized treatments. For instance, according to an article published in the American Society for Clinical Pharmacology & Therapeutics (ASCPT) in 2023, a study comparing the effectiveness of generic clopidogrel and its brand-name counterpart for treating patients with acute myocardial infarction (AMI) found that the generic version was equally effective as the brand-name medication in terms of cardiovascular and bleeding outcomes. This signifies that the utilization of generic drugs in personalized treatment has a positive impact, and the personalized medicine approach is likely to bring lucrative opportunities for the branded generic market.

Branded Generics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Branded Generics market analysis are therapeutic application, drug class, formulation type, and distribution channel.

• Based on therapeutic application, the branded generics market is segmented into oncology, cardiovascular diseases, gastrointestinal diseases, diabetes, neurology, dermatology diseases, analgesics & anti-inflammatory, and others. The others segment held the largest market share in 2023.
• By drug class, the market is segmented into antimetabolites, hormones, antihypertensive, alkylating agents, lipid-lowering drugs, antidepressants, antipsychotics, antiepileptics, and others. The others segment held the largest share of the market in 2023.
• Based on formulation type, the branded generics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2023.
• In terms of distribution channels, the market is categorized into hospitals, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment held a significant share of the market in 2023.

Branded Generics Market Share Analysis by Geography

The geographic scope of the Branded Generics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market. The generic drug utility has increased the share of pharmaceutical spending. According to an article published in the National Library of Medicine (NLM), over 90 % of pharmaceutical drug prescriptions in the US are currently dispensed as generic drugs. As per the report published by the Food and Drug Administration (FDA) in 2020, First generics are essential to public health; 72 first generic drugs received FDA approval in 2020. In addition, the FDA estimated that branded generic drugs have helped the healthcare system save US$ 2.2 trillion in the past decade. Due to rising utilization of branded generics in the region, North America held the largest share in 2023. Asia Pacific is projected to register the highest CAGR in the coming years.

Branded Generics Market Report Scope

Branded Generics Market News and Recent Developments

The Branded Generics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes essential corporate publications, association data, and databases. A few of the developments in the Branded Generics market are listed below:

• Novartis’Sandoz launched a generic version of AbbVie’s Combigan, a combo eye drop used to treat elevated eye pressure in the U.S. As the most-dispensed branded combo glaucoma medication, the originator reeled in $373 million in U.S. sales in 2021. With the launch, the company is expanding its eye drug offerings.  (Source: Sandoz, Company Website, April 2022)
• GSK agreed to acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for US$ 55 per share of common stock in cash, representing an approximate total equity value of US$ 1.9 billion (£1.5 billion). (Source: GlaxoSmithKline plc., Press Release, April 2022)

Branded Generics Market Report Coverage and Deliverables

The “Branded Generics Market Size and Forecast (2021–2031)” report provides a comprehensive breakdown of the market covering the areas:

• Branded Generics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Branded Generics market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Branded Generics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Branded Generics market
• Detailed company profiles